Publishing of Nexstim Plc 2014 Full Year Results


Helsinki, 4 February 2015 at 1:00 pm

Nexstim  Plc  (NXTMH:HEX,  NXTMS:STO),  a  medical  technology company aiming to
improve rehabilitation for stroke patients through the use of non-invasive brain
stimulation,  will announce its full year results for the year ended 31 December
2014 on Thursday 26 February 2015.

A  conference call  for analysts  will take  place at  15:00 EET on Thursday 26
February  2015 which will hosted by Janne  Huhtala, Chief Executive Officer, and
Mikko  Karvinen, Chief  Financial Officer,  who will  present the  financial and
operational results followed by a Q&A session.

The dial-in numbers for the conference call are:



Helsinki: 0923195187

Stockholm: 0850336434

London: 08006940257

US: 16315107498



The call ID number is 80666514.



NEXSTIM PLC



Janne Huhtala, Chief Executive Officer



For further information please visit www.nexstim.com or contact:


Nexstim                                            +358 40 8615046

Janne Huhtala, Chief Executive Officer   janne.huhtala@nexstim.com

UB Capital Oy (Certified Adviser)                 +358 9 2538 0225

Consilium Strategic Communications             +44 (0)20 3709 5700

Mary-Jane Elliott                      nexstim@consilium-comms.com
Amber Bielecka
Ivar Milligan
Laura Thornton


About Nexstim Plc

Nexstim,  formed in 2000 and  based in Finland,  is a medical technology company
aiming  to improve rehabilitation for stroke patients. Nexstim has pioneered its
technology  in  brain  diagnostics  with  the  Navigated Brain Stimulation (NBS)
system  as the first  and only FDA-cleared  and CE-marked navigated Transcranial
Magnetic  Stimulation (nTMS)  device for  pre-surgical mapping  of the motor and
speech  cortices.  Based  on  the  same  technology  platform,  the  company has
developed  a device for stroke therapy called Navigated Brain Therapy (NBT®). In
H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the
US  aiming to demonstrate the  effectiveness of NBT® and  gain FDA clearance for
commercialisation  in post-acute stroke therapy  in the US. Nexstim's shares are
listed  on Nasdaq First  North Finland and  Nasdaq First North  Sweden. For more
information please visit www.nexstim.com.




[HUG#1891658]

Pièces jointes

Publishing of Nexstim Plc 2014 Full Year Results.pdf